Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
41. |
ECCT/25/09/01 | VLA1553-404 VLA1553-404: A Pragmatic Randomised Controlled Trial to Evaluate the Effectiveness and Safety of VLA1553 against Chikungunya Virus Disease |
Principal Investigator(s) 1. Prof. Videlis Nduba Site(s) in Kenya 1. KEMRI-MTWAPA (Kilifi county) |
21-01-2026 |
View |
42. |
ECCT/25/07/01 | FIH Study of CLY-124 A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county) 2. Victoria Biomedical Research Institute [VIBRI] (Kisumu county) |
18-12-2025 |
View |
43. |
ECCT/25/02/01 | IMPAACT 2037 Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 |
Principal Investigator(s) 1. Lucy C. Koech Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project |
18-12-2025 |
View |
44. |
ECCT/25/05/01 | Sparkle Study Site 1403 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive CrisesA phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Gertrudes Children’s Hospital (Nairobi City county) |
18-12-2025 |
View |
45. |
ECCT/25/07/08 | REACH Heat-stable carbetocin for the treatment of postpartum haemorrhage: a phase III, randomized, double-blind, active controlled, multicountry, multicentre, non-inferiority trial |
Principal Investigator(s) 1. Zahida Qureshi Site(s) in Kenya 1. Machakos county hospital (Machakos county) 2. Pumwani maternity hospital (Nairobi City county) 3. Nakuru Level 5 Hospital (Nakuru county) |
17-12-2025 |
View |
46. |
ECCT/25/03/05 | Sparkle Study -Site 1402 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Site 1401: Victoria Biomedical Research Institute (Kisumu county) 2. Site 1402: Ahero Clinical trials Unit (Kisumu county) 3. Site 1403: International Cancer Institute (Uasin Gishu county) 4. Site 1404: Kondele Childrens Hospital (Kisumu county) 5. Site 1405: KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Site 1406: Gertrude’s Children’s Hospital. (Nairobi City county) |
16-12-2025 |
View |
47. |
ECCT/25/05/02 | Hibiscus 2 - Site 251 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Site 251 - Ahero Clinical Trails Unit, CREATES Strathmore University (Kisumu county) |
16-12-2025 |
View |
48. |
ECCT/25/08/06 | MK-8527-010 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women |
Principal Investigator(s) 1. Irene Wambui Inwani Site(s) in Kenya 1. UW-KNH; Rachuonyo County Hospital, Oyugis (Homa Bay county) 2. KEMRI-CMR-RCTP KEMRI CIS Building (Kisumu county) 3. Kargeno Research & Policy Hub (Kisumu county) 4. KEMRI-CCR-PHRD, Thika site (Kiambu county) |
15-12-2025 |
View |
49. |
ECCT/25/08/03 | Cabotegravir + Rilpivirine Lon A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long acting Combination Therapy Studies |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. Moi University Clinical Research Centre (Uasin Gishu county) 3. KEMRI-WRP (Kericho county) 4. Kenyatta National Hospital Comprehensive Care Centre (Nairobi City county) |
15-12-2025 |
View |
50. |
ECCT/25/08/07 | ACCEDE Usability Study USABILITY, ACCEPTABILITY, FEASIBILITY AND COST OF CONTINUOUS GLUCOSE MONITORING BY PERSONS LIVING WITH TYPE 1 DIABETES MELLITUS, HEALTH CARE PROVIDERS AND CAREGIVERS AT THE PAEDIATRIC AND ADOLESCENT ENDOCRINOLOGY CLINIC IN KENYATTA NATIONAL HOSPITAL |
Principal Investigator(s) 1. Prisca Amolo Site(s) in Kenya Kenyatta National Hospital |
10-12-2025 |
View |